Business Description Avanir Pharmaceuticals is an emerging specialty pharmaceuticals and antibody generation services company engaged in the discovery, development and licensing of therapeutic products to treat chronic human diseases. In July 2000, the United States Food and Drug Administration approved the new drug application for the Company's lead therapeutic product, docosanol 10% cream, a topical treatment for recurrent oral-facial herpes infections, commonly known as cold sores and fever blisters. SmithKline Beecham began manufacturing and distributing docosanol 10% cream for the Company in the United States under the trade name Abreva in October 2000 under an exclusive license agreement for the North American market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.